Novartis Hikes Sandoz Sales Guide As Separation Edges Closer
As Sandoz Biopharm Contact Manufacturing Unit Moved To Novartis IM Segment
Executive Summary
Novartis reported 8% top-line growth for its Sandoz unit during the first quarter of 2023, one of the last before it is separated into a standalone company.
You may also be interested in...
Generics Bulletin Explains: Sandoz’s Spinoff From Novartis
Ahead of a Sandoz capital markets day on 8 June, Generics Bulletin explains what we know so far about the firm’s spinoff from parent company Novartis – as well as the questions that the companies are yet to answer.
Sandoz Reveals New Headquarters Post Spin, Mid-2024 Date Outlined
Tracing its roots back to Basel in the late nineteenth century, Sandoz has confirmed the location of its new planned permanent headquarters post-spin.
Sandoz Moves Ahead With High-Concentration Adalimumab In Europe
Sandoz has received a formal European approval for its high-concentration Hyrimoz biosimilar rival to Humira, setting the stage for it to enter a market that also includes versions from Alvotech/Stada and Celltrion.